Inherited iron loading: Genetic testing in diagnosis and management

Blood Reviews

Volumn 19, Issue 2, 2005, Pages 69-88

  Worwood, Mark ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Clinical penetrance; Ferritin; Ferroportin 1; Haemochromatosis; Hepcidin; HFE; Iron absorption; Iron overload; Neurodegeneration; Transferrin; Transferrin receptor

Indexed keywords

DEFEROXAMINE; FERRITIN; HEPCIDIN; TRANSFERRIN;

AUTOSOMAL RECESSIVE INHERITANCE; CHROMOSOME 1; DEGENERATIVE DISEASE; DIET; GENE IDENTIFICATION; GENE MUTATION; HEMOCHROMATOSIS; HUMAN; IRON ABSORPTION; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; LIVER PARENCHYMA; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW;

EID: 10444286640     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2004.03.003     Document Type: Article

References (175)

1. Bothwell T.H., Charlton R.W., Cook J.D., Finch C.A. Iron metabolism in man. 1979;Blackwell Scientific Publications, Oxford
2. Miret S., Simpson R.J., Mckie A.T. Physiology and molecular biology of dietary iron absorption. Ann. Rev. Nutr. 23:2003;283-301
3. Cavill I., Worwood M., Jacobs A. Internal regulation of iron absorption. Nature. 256:1975;328-329
4. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 102:2003;783-788
5. Nicolas G., Bennoun M., Devaux I., Beaumont C., Grandchamp B., Kahn A., et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc. Natl. Acad. Sci. USA. 98:2001;8780-8785
6. Nicolas G., Viatte L., Lou D.Q., Bennoun M., Beaumont C., Kahn A., et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat. Genet. 34:2003;97-101
7. Ahmad K.A., Ahmann J.R., Migas M.C., Waheed A., Britton R.S., Bacon B.R., et al. Decreased liver hepcidin expression in the Hfe knockout mouse. Blood Cells Mol. Dis. 29:2002;361-366
8. Feder J.N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D.A., Basava A., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 13:1996;399-408
9. The UK Haemochromatosis Consortium, Worwood M. A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut 1997;41:841-4
10. Jackson H.A., Carter K., Darke C., Guttridge M.G., Ravine D., Hutton R.D., et al. HFE mutations, iron deficiency and overload in 10,500 blood donors. British Journal of Haematology. 114:2001;474-484
11. Bothwell T.H., Macphail A.P. Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Semin. Hematol. 35:1998;55-71
12. Simon M., Pawlotsky Y., Bourel M., Fauchet R., Genetet B. Hémochromatose idopathique. Maladie associée à l'antigène tissulaire HL-A3? Nouv. Presse Med. 4:1975;1432
13. Simon M., Le Mignon L., Fauchet R., Yaouanq J., David V., Edan G., et al. A study of 609 HLA haplotypes marking for the hemochromatosis gene: (1) mapping of the gene near the HLA-A locus and characters required to define a heterozygous population and (2) hypothesis concerning the underlying cause of hemochromatosis-HLA association. Am. J. Hum. Genet. 41:1987;89-105
14. Raha-Chowdhury R., Bowen D.J., Stone C., Pointon J.J., Terwilliger J.D., Shearman J.D., et al. New polymorphic microsatellite markers place the haemochromatosis gene telomeric to D6S105. Hum. Mol. Genet. 4:1995;1869-1874
15. Santos M., Schilham M.W., Rademakers L.H.P.M., Marx J.J.M., Desousa M., Clevers H. Defective iron homeostasis in β2-microglobulin knockout mice recapitulates hereditary hemochromatosis in man. J. Exp. Med. 184:1996;1975-1985
16. Zhou X.Y., Tomatsu S., Fleming R.E., Parkkila S., Waheed A., Jiang J.X., et al. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc. Natl. Acad. Sci. USA. 95:1998;2492-2497
17. Fleming R.E., Holden C.C., Tomatsu S., Waheed A., Brunt E.M., Britton R.S., et al. Mouse strain differences determine severity of iron accumulation in Hfe knockout model of hereditary hemochromatosis. Proc. Natl. Acad. Sci. USA. 98:2001;2707-2711
18. Feder J.N., Penny D.M., Irrinki A., Lee V.K., Lebron J.A., Watson N., et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc. Natl. Acad. Sci. USA. 95:1998;1472-1477
19. Roy C.N., Penny D.M., Feder J.N., Enns C.A. The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells. J. Biol. Chem. 274:1999;9022-9028
20. Riedel H.D., Muckenthaler M.U., Gehrke S.G., Mohr I., Brennan K., Herrmann T., et al. HFE downregulates iron uptake from transferrin and induces iron- regulatory protein activity in stably transfected cells. Blood. 94:1999;3915-3921
21. Feeney G.P., Worwood M. The effects of wild-type and mutant HFE expression upon cellular iron uptake in transfected human embryonic kidney cells. Biochim. Biophys. Acta - Mol. Cell Res. 1538:2001;242-251
22. Townsend A., Drakesmith H. Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease, and secondary iron overload. Lancet. 359:2002;786-790
23. Bridle K.R., Frazer D.M., Wilkins S.J., Dixon J.L., Purdie D.M., Crawford D.H.G., et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homeostasis. Lancet. 361:2003;669-673
24. Muckenthaler M., Richter A., Gunkel N., Riedel D., Polycarpou-Schwarz M., Hentze S., et al. Relationships and distinctions in iron-regulatory networks responding to interrelated signals. Blood. 101:2003;3690-3698
25. Zoller H., Theurl I., Koch R.O., Mckie A.T., Vogel W., Weiss G. Duodenal cytochrome b and hephaestin expression in patients with iron deficiency and hemochromatosis. Gastroenterology. 125:2003;746-754
26. Nicolas G., Chauvet C., Viatte L., Danan J.L., Bigard X., Devaux I., et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 110:2002;1037-1044
27. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 102:2003;783-788
28. Ajioka R.S., Jorde L.B., Gruen J.R., Yu P., Dimitrova D., Barrow J., et al. Haplotype analysis of hemochromatosis: evaluation of different linkage-disequilibrium approaches and evolution of disease chromosomes. Am. J. Hum. Genet. 60:1997;1439-1447
29. Thomas W., Fullan A., Loeb D.B., Mcclelland E.E., Bacon B.R., Wolff R.K. A haplotype and linkage disequilibrium analysis of the hereditary hemochromatosis gene region. Hum. Genet. 102:1998;517-525
30. Raha-Chowdhury R., Gruen J.R. Localization, allelic heterogeneity, and origins of the hemochromatosis gene. Barton J.C., Edwards C.Q. Hemochromatosis: Genetics, pathophysiology, diagnosis and treament. 2000;75-90 Cambridge University Press, Cambridge
31. Merryweather-Clarke A.T., Pointon J.J., Jouanolle A.M., Rochette J., Robson K.J.H. Geography of HFE C282Y and H63D mutations. Genet. Test. 4:2000;183-198
32. Rochette J., Pointon J.J., Fisher C.A., Perera G., Arambepola M., Arichchi D.S.K., et al. Multicentric origin of hemochromatosis gene (HFE) mutations. Am. J. Hum. Genet. 64:1999;1056-1062
33. Mura C., Raguenes O., Ferec C. HFE mutations in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood. 93:1999;2202-2205
34. Arya N., Chakrabrati S., Hegele R.A., Adams P.C. HFE S65C variant is not associated with increased transferrin saturation in voluntary blood donors. Blood Cells Mol. Dis. 25:1999;354-357
35. Holmstrom P., Marmur J., Eggertsen G., Gafvels M., Stal P. Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls. Gut. 51:2002;723-730
36. Salvioni A., Mariani R., Oberkanins C., Moritz A., Mauri V., Pelucchi S., et al. Prevalence of C282Y and E168X HFE mutations in an Italian population of Northern European ancestry. Haematologica. 88:2003;250-255
37. Koefoed P., Dalhoff K., Dissing J., Kramer I., Milman N., Pedersen P., et al. HFE mutations and hemochromatosis in Danish patients admitted for HFE genotyping. Scand. J. Clin. Lab. Invest. 62:2002;527-535
38. Candore G., Mantovani V., Balistreri C.R., Lio D., Colonna-Romano G., Cerreta V., et al. Frequency of the HFE gene mutations in five Italian populations. Blood Cells Mol. Dis. 29:2002;267-273
39. Couto A.R., Peixoto M.J., Garrett F., Laranjeira F., Cipriano T., Armas J.B. Linkage disequilibrium between S65C HFE mutation and HLA A29- B44 haplotype in Terceira Island, Azores. Hum. Immunol. 64:2003;625-628
40. Pietrapertosa A., Vitucci A., Campanale D., Palma A., Renni R., Delios G., et al. HFE gene mutations an Apulian population: allele frequencies. Eur. J. Epidemiol. 18:2003;685-689
41. Willis G., Wimperis J.Z., Smith K., Fellows I.W., Jennings B.A. HFE mutations in the elderly. Blood Cells Mol. Dis. 31:2003;240-246
42. Jeffrey G., Chakrabarti S., Hegele R., Adams P. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homzygote prevalence in haemochromatosis. Nat. Genet. 22:1999;325-326
43. Somerville M.J., Sprysak K.A., Hicks M., Elyas B.G., Vicen-Wyhony L. An HFE intronic variant promotes misdiagnosis of hereditary hemochromatosis. Am. J. Hum. Genet. 65:1999;924-926
44. Merryweather-Clarke A.T., Pointon J.J., Shearman J.D., Robson K.J.H., Jouanolle A.M., Mosser A., et al. Polymorphism in intron 4 of HFE does not compromise haemochromatosis mutation results. Nat. Genet. 23:1999;271
45. Motulsky A.G. Genetics of hemochromatosis. N. Engl. J. Med. 301:1979;1291
46. Powell L.W., Summers K.M., Board P.G., Axelsen E., Webb S., Halliday J.W. Expression of hemochromatosis in homozygous subjects. Implications for early diagnosis and prevention. Gastroenterology. 98:1990;1625-1632
47. Adams P.C. Prevalence of abnormal iron studies in heterozygotes for hereditary hemochromatosis: an analysis of 255 heterozygotes. Am. J. Hematol. 45:1994;146-149
48. Bulaj Z.J., Griffen L.M., Jorde L.B., Edwards C.Q., Kushner J.P. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N. Engl. J. Med. 335:1996;1799-1805
49. Burt M.J., George P.M., Upton J.D., Collett J.A., Frampton C.M.A., Chapman T.M., et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut. 43:1998;830-836
50. Datz C., Haas T., Rinner H., Sandhofer F., Patsch W., Paulweber B. Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: a protective role against iron deficiency? Clin. Chem. 44:1998;2429-2432
51. Beutler E., Felitti V., Gelbart T., Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann. Internal Med. 133:2000;329-337
52. Rossi E., Olynyk J.K., Cullen D.J., Papadopoulos G., Bulsara M., Summerville L., et al. Compound heterozygous hemochromatosis genotype predicts increased iron and erythrocyte indices in women. Clin. Chem. 46:2000;162-166
53. Beutler E., Felitti V.J., Koziol J.A., Ho N.J., Gelbart T. Penetrance of 845G. → A (C282Y) HFE hereditary haemochromatosis mutation in the USA Lancet. 359:2002;211-218
54. Edwards C.Q., Griffen L.M., Bulaj Z.J., Ajioka R.S., Kushner J.P. The iron phenotype of hemochromatosis heterozygotes. Barton J.C., Edwards C.Q. Hemochromatosis: genetics, pathophysiology, diagnosis and treatment. 2000;411-418 Cambridge University Press, Cambridge
55. Wallace D.F., Walker A.P., Pietrangelo A., Clare M., Bomford A.B., Dixon J.L., et al. Frequency of the S65C mutation of HFE and iron overload in 309 subjects heterozygous for C282Y. J. Hepatol. 36:2002;474-479
56. Asberg A., Thorstensen K., Hveem K., Bjerve K.S. Hereditary hemochromatosis: the clinical significance of the S65C mutation. Genet. Test. 6:2002;59-62
57. Fletcher L.M., Dixon J.L., Purdie D.M., Powell L.W., Crawford D.H.G. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology. 122:2002;281-289
58. Van Vlierberghe H., Langlois M., Delanghe J., Horsmans Y., Michielsen P., Cartuyvels R., et al. Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. J. Hepatol. 35:2001;707-711
59. Beutler E., Gelbart T., Lee P. Haptoglobin polymorphism and iron homeostasis. Clin. Chem. 48:2002;2232-2235
60. Carter K., Bowen D.J., McCune C.A., Worwood M. Haptoglobin type neither influences iron accumulation in normal subjects nor predicts clinical presentation in HFE C282Y haemochromatosis: phenotype and genotype analysis. Brit. J. Haematol. 122:2003;326-332
61. Dooley J, Worwood M. Guidelines on diagnosis and therapy: Genetic haemochromatosis. British Committee for Standards in Haematology. 2000. Abingdon, Oxford, Darwin Medical Communications Ltd. Available www.bcshguidelines.com
62. Mcdonnell S.M., Preston B.L., Jewell S.A., Barton J.C., Edwards C.Q., Adams P.C., et al. A survey of 2851 patients with hemochromatosis: symptoms and response to treatment. Am. J. Med. 106:1999;619-624
63. Distante S. Phenotypic expression of the HFE gene mutation (C282Y) among the hospitalised population. Gut. 47:2000;575-579
64. Guyader D., Jacquelinet C., Moirand R., Turlin B., Mendler M.H., Chaperon J., et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology. 115:1998;929-936
65. Bassett M.L., Halliday J.W., Powell L.W. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology. 6:1986;24-29
66. Adams P.C., Bradley C., Henderson A.R. Evaluation of the hepatic iron index as a diagnostic criterion for genetic hemochromatosis. J. Lab Clin. Med. 130:1997;509-514
67. Nielsen P., Engelhardt R., Dullmann J., Fischer R. Non-invasive liver iron quantification by SQUID- biosusceptometry and serum ferritin iron as new diagnostic parameters in hereditary hemochromatosis. Blood Cells Mol. Dis. 29:2002;451-458
68. Brittenham G.M. Noninvasive methods for the early detection of hereditary hemochromatosis. Ann. N.Y. Acad. Sci. 526:1988;199-208
69. Brittenham G.M., Badman D.G. Noninvasive measurement of iron: report of an NIDDK workshop. Blood. 101:2003;15-19
70. Worwood M. What is the role of genetic testing in diagnosis of haemochromatosis? Ann. Clin. Biochem. 38:2001;3-19
71. Cohen P. Whose rights are they anyway? New Scientist. 2000;10
72. Biasiotto G., Belloli S., Ruggeri G., Zanella I., Gerardi G., Corrado M., et al. Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload. Clin. Chem. 49:2003;1981-1988
73. Niederau C., Fischer R., Purschel A., Stremmel W., Haussinger D., Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 110:1996;1107-1119
74. Walters G.O., Miller F.M., Worwood M. Serum ferritin concentration and iron stores in normal subjects. J. Clin. Pathol. 26:1973;770-772
75. Witte D.L., Crosby W.H., Edwards C.Q., Fairbanks V.F., Mitros F.A. Hereditary hemochromatosis. Clin. Chim. Acta. 245:1996;139-200
76. Asberg A., Hveem K., Kruger O., Bjerve K.S. Persons with screening-detected haemochromatosis: as healthy as the general population? Scand. J. Gastroenterol. 37:2002;719-724
77. McCune C.A., Al-Jader L.N., May A., Hayes S.L., Jackson H.A., Worwood M. Hereditary haemochromatosis: only 1% of adult HFE C282Y homozygotes in South Wales have a clinical diagnosis of iron overload. Hum. Genet. 111:2002;538-543
78. Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood. 101:2003;3347-3350
79. Ajioka R.S., Kushner J.P. Clinical consequences of iron overload in hemochromatosis homozygotes. Blood. 101:2003;3351-3354
80. Ajioka R.S., Kushner J.P. Rebuttal to Beutler. Blood. 101:2003;3358
81. Beutler E. Clinical consequences of iron overload in hemochromatosis homozygotes - Rebuttal to Ajioka and Kushner. Blood. 101:2003;3354-3357
82. McCune A., Worwood M. Penetrance in hereditary hemochromatosis - to the editor. Blood. 102:2003;2696
83. Moirand R., Guyader D., Mendler M.H., Jouanolle A.M., Le Gall J.Y., David V., et al. HFE based re-evaluation of heterozygous hemochromatosis. Am. J. Med. Genet. 111:2002;356-361
84. Nelson R.L. Dietary iron and colorectal-cancer risk. Free Radical Biol. Med. 12:1992;161-168
85. Sullivan J.L. Iron and the sex difference in heart disease risk. Lancet. 1:1981;1293-1294
86. Kent S., Weinberg E. Hypoferremia - adaptation to disease. N. Engl. J. Med. 320:1989;672
87. Halliwell B., Gutteridge J.M.C. Oxygen-toxicity, oxygen radicals, transition-metals and disease. Biochem. J. 219:1984;1-14
88. Thompson K.J., Shoham S., Connor J.R. Iron and neurodegenerative disorders. Brain Res. Bull. 55:2001;155-164
89. Worwood M. HFE mutations as risk factors in disease. Best Pract. Res. Clin. Haematol. 15:2002;295-314
90. Roest M., van der Schouw Y.T., deValk B., Marx J.J.M., Tempelman M.J., deGroot P.G., et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation. 100:1999;1268-1273
91. Willis G., Wimperis J.Z., Lonsdale R., Fellows I.W., Watson M.A., Skipper L.M., et al. Incidence of liver disease in people with HFE mutations. Gut. 46:2000;401-404
92. Ellervik C., Mandrup-Poulsen T., Nordestgaard B.G., Larsen L.E., Appleyard M., Frandsen M., et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet. 358:2001;1405-1409
93. Shaheen N.J., Silverman L.M., Keku T., Lawrence L.B., Rohlfs E.M., Martin C.F., et al. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J. Natl. Cancer Inst. 95:2003;154-159
94. Dorak M.T., Burnett A.K., Worwood M., Sproul A.M., Gibson B.E.S. The C282Y mutation of hfe is another male specific risk factor childhood acute lymphoblastic leukemia. Blood. 94:1999;3957-3958
95. Nelson R.L., Davis F.G., Persky V., Becker E. Risk of neoplastic and other diseases among people with heterozygosity for hereditary hemochromatosis. Cancer. 76:1995;875-879
96. Hannuksela J., Savolainen E.-R., Koistinen P., Parkkila S. Prevalence of HFE genotypes, C282Y and H63D in patients with hematologic disorders. Haematologica. 87:2002;131-135
97. Xie Y.G., Lillicrap D.P., Taylor S.A.M. An association between the common hereditary hemochromatosis mutation and the factor V Leiden allele in a population with thrombosis. Blood. 92:1998;1461-1462
98. Brown K., Luddington R., Taylor S.A.M., Lillicrap D.P., Baglin T.P. Risk of venous thromboembolism associated with the common hereditary haemochromatosis Hfe gene (C282Y) mutation. Brit. J. Haematol. 105:1999;95-97
99. McLean R.M., Feeney G.P., Bowley S.J., Bowen D.J., Worwood M., Collins P.W. Factor V Leiden and the common haemochromatosis mutation HFE C282Y: is there an association in familial venous thromboembolic disease? Brit. J. Haematol. 107:1999;210-212
100. Simon M. Secondary iron overload and the haemochromatosis allele. Brit. J. Haematol. 60:1985;1-5
101. Roberts A.G., Whatley S.D., Morgan R.R., Worwood M., Elder G.H. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet. 349:1997;321-323
102. Elder G.H., Worwood M. Mutations in the hemochromatosis gene, porphyria cutanea tarda, and iron overload. Hepatology. 27:1998;289-291
103. Bulaj Z.J., Phillips J.D., Ajioka R.S., Franklin M.R., Griffen L.M., Guinee D.J., et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood. 95:2000;1565-1571
104. Tannapfel A., Stolzel U., Kostler E., Melz S., Richter M., Keim V., et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virch. Arch. - Int. J. Pathol. 439:2001;1-5
105. Brady J.J., Jackson H.A., Roberts A.G., Morgan R.R., Whatley S.D., Rowlands G.L., et al. Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. J. Invest. Dermatol. 115:2000;868-874
106. Sampietro M., Piperno A., Lupica L., Arosio C., Vergani A., Corbetta N., et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology. 27:1998;181-184
107. Bonkovsky H.L., Pohfitzpatrick M., Pimstone N., Obando J., Dibisceglie A., Tattrie C., et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology. 27:1998;1661-1669
108. Rees D.C., Luo L.Y., Thein S.L., Singh B.M., Wickramasinghe S. Nontransfusional iron overload in thalassemia: association with hereditary hemochromatosis. Blood. 90:1997;3234-3236
109. Borgna-Pignatti C., Solinas A., Bombieri C., Micciolo R., Gamberini M.R., Destefano P., et al. The haemochromatosis mutations do not modify the clinical picture of thalassaemia major in patients regularly transfused and chelated. Brit. J. Haematol. 103:1998;813-816
110. Longo F., Zecchina G., Sbaiz L., Fischer R., Piga A., Camaschella C. The influence of hemochromatosis mutations on iron overload of thalassemia major. Haematologica. 84:2002;799-803
111. Piperno A., Mariani R., Arosio C., Vergani A., Bosio S., Fargion S., et al. Haemochromatosis in patients with β-thalassaemia trait. Brit. J. Haematol. 111:2000;908-914
112. Melis M.A., Cau M., Deidda F., Barella S., Cao A., Galanello R. H63D mutation in the HFE gene increases iron overload in β-thalassemia carriers. Haematologica. 87:2002;242-245
113. Yaouanq J., Grosbois B., Jouanolle A.M., Goasguen J., Leblay R. Haemochromatosis Cys282Tyr mutation in pyridoxine-responsive sideroblastic anaemia. Lancet. 349:1997;1475-1476
114. Cotter P.D., May A., Li L.P., Alsabah A.I., Fitzsimons E.J., Cazzola M., et al. Four new mutations in the erythroid-specific 5- aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: Increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis. Blood. 93:1999;1757-1769
115. Zanella A., Bianchi P., Iurlo A., Boschetti C., Taioli E., Vercellati C., et al. Iron status and HFE genotype in erythrocyte pyruvate kinase deficiency: Study of Italian cases. Blood Cells Mol. Dis. 27:2001;653-661
116. Brandenberg J.B., Biasiutti F.D., Lutz H.U., Wuillemin W.A. Hereditary spherocytosis and hemochromatosis. Ann. Hematol. 81:2002;202-209
117. Allen K., Williamson R. Screening for hereditary haemochromatosis should be implemented now. Brit. Med. J. 320:2000;183-184
118. Papanikolaou G, Samuels ME, Ludwig EH,, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2003; published online 30 November
119. Roetto A., Papanikolaou G., Politou M., Alberti F., Girelli D., Christakis J., et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat. Genet. 33:2003;21-22
120. Roetto A, Daraio F, Portorato P. Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70r). Blood 2003; online publication November
121. Camaschella C., Roetto A., Cali A., De Gobbi M., Garozzo G., Carella M., et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat. Genet. 25:2000;14-15
122. Girelli D., Bozzini C., Roetto A., Alberti F., Daraio F., Colombari R., et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology. 122:2002;1295-1302
123. Roetto A., Totaro A., Piperno A., Piga A., Longo F., Garozzo G., et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood. 97:2001;2555-2560
124. Donovan A., Brownlie A., Zhou Y., Shepard J., Pratt S.J., Moynihan J., et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 403:2000;776-781
125. Mckie A.T., Marciani P., Rolfs A., Brennan K., Wehr K., Barrow D., et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell. 5:2000;299-309
126. Abboud S., Haile D.J. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J. Biol. Chem. 275:2000;19906-19912
127. Devalia V., Carter K., Walker A.P., Perkins S.J., Worwood M., May A., et al. Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3). Blood. 100:2002;695-697
128. Gordeuk V.R., Caleffi A., Corradini E. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol. Dis. 31:2003;299-304
129. Beutler E., Barton J.C., Felitti V.J., et al. Ferroportin 1 (SCL40A1) variant associated with iorn overload in African Americans. Blood Cells Mol. Dis. 31:2003;305-309
130. Kelly D.A. Current results and evolving indications for liver transplantation in children. J. Pediatr. Gastroenterol. Nutr. 27:1998;214-221
131. Kelly A.L., Lunt P.W., Rodrigues F., Berry P.J., Flynn D.M., McKiernan P.J., et al. Classification and genetic features of neonatal haemochromatosis: a study of 27 affected pedigrees and molecular analysis of genes implicated in iron metabolism. J. Med. Genet. 38:2001;599-610
132. Gordeuk V.R. African iron overload. Semin. Hematol. 39:2002;263-269
133. Gordeuk V.R., Mclaren C.E., Macphail A.P., Deichsel G., Bothwell T.H. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited. Blood. 87:1996;3470-3476
134. Beutler E., Gelbart T., Lee P., Trevino R., Fernandez M.A., Fairbanks V.F. Molecular characterization of a case of atransferrinemia. Blood. 96:2000;4071-4074
135. Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathology. 23:2003;345-350
136. Loreal O., Turlin B., Pigeon C., Moisan A., Ropert M., Morice P., et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J. Hepatol. 36:2002;851-856
137. Cossu G., Melis M., Floris G., Hayflick S.J., Spissu A. Hallervorden Spatz syndrome (pantothenate kinase associated neurodegeneration) in two Sardinian brother with homozygous mutation in PANK 2 gene. J. Neurol. 249:2002;1599-1600
138. Crompton D.E., Chinnery P.F., Fey C., Curtis A.R.J., Morris C.M., Kierstan J., et al. Neuroferritinopathy: a window on the role of iron in neurodegeneration. Blood Cells Mol. Dis. 29:2002;522-531
139. Curtis A.R.J., Fey C., Morris C.M., Bindoff L.A., Ince P.G., Chinnery P.F., et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28:2001;350-354
140. Alper G., Narayanan V. Friedreich's ataxia. Pediatr. Neurol. 28:2003;335-341
141. Park S., Gakh O., O'Neill H.A., Mangravita A., Nichol H., Ferreira G.C., et al. Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation. J. Biol. Chem. 278:2003;31340-31351
142. Becker E., Richardson D.R. Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. Int. J. Biochem. Cell Biol. 33:2001;1-10
143. Ke Y., Qian Z.M. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol. 2:2003;246-253
144. Pulliam J.F., Jennings C.D., Kryscio R.J., Davis D.G., Wilson D., Montine T.J., et al. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am. J. Med. Genet. Part B - Neuropsychiatr. Genet. 119B:2003;48-53
145. Combarros O., Garcia-Roman M., Fontalba A., Fernandez-Luna J.L., Llorca J., Infante J., et al. Interaction of the H63D mutation in the hemochromatosis gene with the apolipoprotein E epsilon 4 allele modulates age at onset of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 15:2003;151-154
146. Sampietro M., Caputo L., Casatta A., Meregalli M., Pellagatti A., Tagliabue J., et al. The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol. Ageing. 22:2001;563-568
147. Candore G., Licastro F., Chiappelli M., Franceschi C., Lio D., Balistreri C.R., et al. Association between the HFE mutations and unsuccessful ageing: a study in Alzheimer's disease patients from Northern Italy. Mech. Ageing Develop. 124:2003;525-528
148. Buchanan D.D., Silburn P.A., Chalk J.B., Le Couteur D.G., Mellick G.D. The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. Neurosci. Lett. 327:2002;91-94
149. Henz S., Reichen J., Liechti-Gallati S. HLA-H gene mutations and haemochromatosis: the likely association of H63D with mild phenotype and the detection of S65C, a novel variant in exon 2. J. Hepatol. 26:1997;57
150. Barton J.C., Sawadahirai R., Rothenberg B.E., Acton R.T. Two novel missense mutations of the HFE gene (I105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands. Blood Cells Mol. Dis. 25:1999;146-154
151. Piperno A., Arosio C., Fossati L., Vigano M., Trombini P., Vergani A., et al. Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis. Gastroenterology. 119:2000;441-445
152. deVilliers J.N.P., Hillermann R., Loubser L., Kotze M.J. Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. Hum. Mol. Genet. 8:1999;1517-1522
153. Pointon J.J., Wallace D., Merryweather-Clarke A.T., Robson K.J.H. Uncommon mutations and polymorphisms in the hemochromatosis gene. Genet. Test. 4:2000;151-161
154. Steiner M., Ocran K., Genschel J., Meier P., Gerl H., Ventz M., et al. A homozygous HFE gene splice site mutation (IVS5. + 1 G/A) a hereditary hemochromatosis patient of Vietnamese origin Gastroenterology. 122:2002;789-795
155. Wallace D.F., Dooley J.S., Walker A.P. A novel mutation of HFE explains the classical phenotype of genetic hemochromatois in a C282Y heterozygote. Gastroenterology. 116:1999;1409-1412
156. ′ flanking region of the HFE gene: linkage disequilibrium and relationship to iron homeostasis Blood Cells Mol. Dis. 28:2002;191-195
157. Totaro A., Grifa A., Carella M., Dambrosio L., Valentino M., Roth M.P., et al. Hereditary hemochromatosis: a Hpal polymorphism within the HLA-H gene. Mol. Cell Probe. 11:1997;229-230
158. Beutler E., Gelbart T. A common intron 3 mutation (IVS3-48c. → g) leads to misdiagnosis of the c.845G → A (C282Y) HFE gene mutation Blood Cells Mol. Dis. 26:2000;229-233
159. Douabin-Gicquel V., Soriano N., Ferran H., Wojcik F., Palierne E., Tamim S., et al. Identification of 96 single nucleotide polymorphisms in eight genes involved in iron metabolism: efficiency of bioinformatic extraction compared with a systematic sequencing approach. Hum. Genet. 109:2001;393-401
160. Girelli D., Bozzini C., Roetto A., Daraio F., Colombari R., Corrocher R., et al. A new mutation in transferrin receptor 2 gene in hemochromatosis type 3. Blood. 98:2001;3
161. Hattori A., Wakusawa S., Hayashi H., Harashima A., Sanae F., Kawanaka M., et al. AVAQ 594-597 deletion of the TfR2 gene in a Japanese family with hemochromatosis. Hepatol. Res. 26:2003;154-156
162. Mattman A., Huntsman D., Lockitch G., Langlois S., Buskard N., Ralston D., et al. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood. 100:2002;1075-1077
163. Hofmann W.K., Tong X.J., Ajioka R.S., Kushner J.P., Koeffler H.P. Mutation analysis of transferrin-receptor 2 in patients with atypical hemochromatosis. Blood. 100:2002;1099-1100
164. Byrnes V., Ryan E., Barrett S., Kenny P., Mayne P., Crowe J. Genetic hemochromatosis, a Celtic disease: is it now time for population screening? Genet. Test. 5:2001;127-130
165. Willis G., Scott D.G.I., Jennings B.A., Smith K., Bukhari M., Wimperis J.Z. HFE mutations in an inflammatory arthritis population. Rheumatology. 41:2002;176-179
166. Campbell S., George D.K., Robb S.D., Spooner R., McDonagh T.A., Dargie H.J., et al. The prevalence of haemochromatosis gene mutations in the West of Scotland and their relation to ischaemic heart disease. Heart. 89:2003;1023-1026
167. Rivard S.R., Lanzara C., Grimard D., Carella M., Simard H., Ficarella R., et al. Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French-Canadian family. Haematologica. 88:2003;824-826
168. Montosi G., Donovan A., Totaro A., Garuti C., Pignatti E., Cassanelli S., et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J. Clin. Invest. 108:2001;619-623
169. Arden K.E., Wallace D.F., Dixon J.L., Summerville L., Searle J.W., Anderson G.J., et al. A novel mutation in ferroportin 1 is associated with haemochromatosis in a Solomon Islands patient. Gut. 52:2003;1215-1217
170. Njajou O.T., Vaessen N., Joosse M., Berghuis B., van Dongen J.W.F., Breuning M.H., et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat. Genet. 28:2001;213-214
171. Hetet G., Devaux I., Soufir N., Grandchamp B., Beaumont C. Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (slc11A3) mutations. Blood. 102:2003;1904-1910
172. Wallace D.F., Pedersen P., Dixon J.L., Stephenson P., Searle J.W., Powell L.W., et al. Novel mutation in ferroponin 1 is associated with autosomal dominant hemochromatosis. Blood. 100:2002;692-694
173. Roetto A., Merryweather-Clarke A.T., Daraio F., Livesey K., Pointon J.J., Barbabietola G., et al. To the editor: a valine deletion of ferroportin 1: a common mutation in hemochromatosis type 4? Blood. 100:2002;733-734
174. Cazzola M., Cremonesi L., Papaioannou M., Soriani N., Kioumi A., Charalambidou A., et al. Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3). Brit. J. Haematol. 119:2002;539-546
175. Jouanolle A.M., Douabin-Gicquel V., Halimi C., Loreal O., Fergelot P., Delacour T., et al. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J. Hepatol. 39:2003;286-289